Skip to main navigation Skip to search Skip to main content

A Refined Population Pharmacokinetic Model-Based Guideline for Individualized PEGasparaginase Dosing in Pediatric Acute Lymphoblastic Leukemia

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

BACKGROUND: In the Dutch Childhood Oncology Group ALL11 protocol, PEGasparaginase dosing was individualized for standard-risk and medium-risk patients with acute lymphoblastic leukemia. After using our pragmatic old guideline, we aimed to improve individualized PEGasparaginase dosing by developing a population pharmacokinetic model-based dosing guideline.

METHOD: After the 3 doses of 1500 IU/m 2 administered in induction, standard-risk patients received 1 individualized dose and medium-risk patients 14, targeting trough activity levels between 100 and 250 IU/L. The effectiveness, adherence, and toxicity of our new dosing guideline was assessed and compared with the old guideline.

RESULTS: In total, 92 patients (714 samples) were included in the new dosing group and 509 patients (4539 samples) were included in the old dosing group. Comparing the effectiveness, we found that 32% (22/67) of patients in the new and 13% (47/354) of patients in the old dosing group were within the target range after the first individualized dose ( P < 0.001). Among medium-risk patients, a median of 3 dose reductions was needed to reach and maintain levels within the target range in the new dosing group compared with 5 in the old dosing group ( P < 0.001). With a continuous PEGasparaginase dosing schedule, target trough activity levels were reached after 2 dose reductions in the new group versus 4 in the old dosing group. The adherence to the new guideline was >99%, with 6/714 recommended doses deviating from the guideline. With exception of a lower proportion of patients with increased (≥grade 3) serum alanine transaminase (34% new vs 64% old, P < 0.05) in the new dosing group, toxicity was comparable between guidelines.

CONCLUSIONS: With the new dosing guideline, fewer dose-reduction steps are necessary to reach and remain within the target. The high adherence rate emphasized its simplicity and practicality, confirming that it can be easily integrated into clinical practice.

Original languageEnglish
Pages (from-to)289-296
Number of pages8
JournalTherapeutic Drug Monitoring
Volume47
Issue number2
DOIs
Publication statusPublished - 1 Apr 2025

Keywords

  • asparaginase TDM
  • evidence-based dosing
  • individual asparaginase dosing
  • pediatric ALL
  • PEGasparaginase
  • Precision Medicine/methods
  • Antineoplastic Agents/administration & dosage
  • Humans
  • Child, Preschool
  • Infant
  • Male
  • Asparaginase/pharmacokinetics
  • Dose-Response Relationship, Drug
  • Models, Biological
  • Adolescent
  • Female
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy
  • Polyethylene Glycols/administration & dosage
  • Child

Fingerprint

Dive into the research topics of 'A Refined Population Pharmacokinetic Model-Based Guideline for Individualized PEGasparaginase Dosing in Pediatric Acute Lymphoblastic Leukemia'. Together they form a unique fingerprint.

Cite this